MedTrace Logo

Serum Ceramides Level in Systemic Lupus Erythematosus (SLE) Patients as a Novel Marker for Renal Impairment

NCT04256577 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2020-02-17

No results posted yet for this study

Summary

1. Estimation of serum ceramides level in SLE patients as anovel marker for renal impairment
2. Correlation serum ceramides level with histological classification of LN,C3,C4,ANA,ANTI DS DNA ,CRP ,ESR , eGFR , creatinine /protein ratio
3. Follow up estimation of ceramides level in LN patients after 3 cycles of treatment

Conditions

  • Systemic Lupus

Interventions

DIAGNOSTIC_TEST

serum ceramides level in blood

Serum ceramides ( sphingolipid measurement, plasma (EDTA as anticoagulant) and serum separation was performed immediately after blood drawing by two-time scentrifugation at 750 x g for 5 min (4°C). Lipid extraction from plasma and/or serum samples (10 µl each) and subsequent LC-MS/MS)

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
17 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-29
Primary Completion
2021-02-28
Completion
2021-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04256577 on ClinicalTrials.gov